Healthspan.

Rapamycin and longevity: what the evidence shows

Evidence grade: Emerging. Lifespan extension is shown in mice. Human data are small trials on proxy measures (vaccine response, infections) and one year-long safety trial with mostly null results. There are no human data on lifespan. See how we grade.

What rapamycin is

Rapamycin, also called sirolimus, is a prescription drug. In the US it is approved, as Rapamune, to prevent organ rejection in kidney transplant patients aged 13 and older, and to treat a rare lung disease called lymphangioleiomyomatosis [1]. It works by blocking mTOR, a key regulatory enzyme, which suppresses parts of the immune system [1]. It is not approved for aging or longevity.

Why longevity researchers are interested

In 2009, a study in Nature reported that rapamycin fed to genetically diverse mice starting at 600 days of age extended both median and maximal lifespan, in males and females. Measured at the age when 90% of mice had died, lifespan rose by 14% in females and 9% in males. The effect was seen at three separate test sites [2]. Starting earlier, at 270 days, also increased survival in an interim analysis [2]. Disease patterns in treated mice did not differ from controls, and the authors suggested rapamycin may work by postponing death from cancer, by slowing aging mechanisms, or both [2]. These were mice. They are the reason for the interest, not evidence that it works in people.

What human studies show

Human data are limited and mostly use proxy measures.

  • In older volunteers, a related mTOR inhibitor (RAD001) improved the response to a flu vaccine by about 20% at doses that were relatively well tolerated. It also reduced the share of T cells carrying PD-1, a receptor that rises with age and dampens T cell signalling [3].
  • In a phase 2a trial of 264 older adults, six weeks of a low-dose combination of two mTOR inhibitors was associated with fewer reported infections over the following year [4].
  • The PEARL trial gave healthy adults placebo, or 5 mg or 10 mg of compounded rapamycin once a week, for 48 weeks. Adverse events were similar across groups. The primary outcome, visceral fat, did not change. Women on 10 mg had improvements in lean tissue mass and self-reported pain, and those on 5 mg reported better emotional well-being and general health. No other significant effects were seen [5].

The doses above describe what trials tested. They are not a recommendation. We know of no human trial that has measured rapamycin's effect on lifespan.

The known risks

The approved label carries a boxed warning. Immunosuppression can increase the risk of infection and the possible development of lymphoma and other cancers, particularly of the skin [1]. The label also lists:

  • raised cholesterol and triglycerides; in kidney transplant trials, high cholesterol occurred in 43–46% of patients on Rapamune versus 23% on placebo
  • impaired wound healing and fluid buildup
  • harm to a developing fetus, and possible impaired fertility
  • reduced response to vaccines, and live vaccines should be avoided
  • serious interactions with drugs that affect the enzyme CYP3A4, and with grapefruit juice [1]

These warnings come from transplant and lung-disease patients on daily dosing. How much of that risk applies to low, intermittent doses in healthy people is not well established. PEARL is one year-long trial, not a long-term safety record [5].

If you are considering it

Rapamycin is a prescription drug. Do not buy it without a prescription, and do not take it without a doctor who knows your full medical history and the medicines you take. Ask what monitoring they would do, such as blood lipids and infection risk. We do not link to any rapamycin products.

Most of what reliably supports healthy aging is less exotic. Start with our foundations protocol and strength protocol.

Frequently asked questions

Does rapamycin extend lifespan?

In mice, yes: a 2009 study showed it extended median and maximal lifespan even when started late in life. In humans, we know of no trial that has measured its effect on lifespan.

Is rapamycin safe for healthy people?

It is a prescription immunosuppressant whose label carries a boxed warning about infections and cancers. A 48-week trial of low weekly doses in healthy adults found adverse events similar to placebo, but long-term safety in healthy people is not established. Talk to a doctor.

Can I get rapamycin without a prescription?

Rapamycin, also called sirolimus, is a prescription drug. Only take it under the care of a doctor who can monitor you.

What did the PEARL trial find?

Over 48 weeks, weekly low-dose rapamycin had adverse events similar to placebo and did not change visceral fat, the primary outcome. Some secondary measures, such as lean mass and pain in women on 10 mg, improved.

What are the side effects of rapamycin?

The approved label lists infection risk, possible lymphoma and skin cancers, raised cholesterol and triglycerides, impaired wound healing, harm to a developing fetus, reduced vaccine response, and interactions with many drugs and grapefruit juice.

Sources

  1. RAPAMUNE (sirolimus) oral solution and tablets: Prescribing Information. DailyMed, U.S. National Library of Medicine (FDA-approved label, Wyeth/Pfizer), 2024. Label revised 10/2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3275b824-3f82-4151-2ab2-0036a9ba0acc
  2. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 2009. https://pubmed.ncbi.nlm.nih.gov/19587680/
  3. mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 2014. https://pubmed.ncbi.nlm.nih.gov/25540326/
  4. TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine, 2018. https://pubmed.ncbi.nlm.nih.gov/29997249/
  5. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY), 2025. https://pubmed.ncbi.nlm.nih.gov/40188830/